0
Outlook Therapeutics, Inc. Banner Image

Outlook Therapeutics, Inc. has reached its limit for free report views

Work for Outlook Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Outlook Therapeutics, Inc.

  • Ticker OTLK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Outlook Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cranbury, New Jersey
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulationMore of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
Outlook Therapeutics, Inc.

Most Recent Annual Report

Outlook Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Outlook Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports